Substance Use Disorders Treatment Options
Impact on your practice
While this is primarily a public awareness campaign rather than a policy change, it may increase referrals to therapists and SUD treatment providers. The campaign emphasizes treatment effectiveness but doesn't directly affect reimbursement, licensing, or practice operations.
Key facts
SAMHSA launching first annual SUD Treatment Month in January 2025
Campaign focuses on awareness and connecting individuals to treatment services
Weekly themes throughout January designed to reduce stigma and promote access
Therapy Companion analysis
SAMHSA's inaugural SUD Treatment Month in January 2025 creates a modest but meaningful opportunity for therapists to position themselves as treatment resources during a nationally coordinated awareness campaign. While this is primarily a public education initiative rather than a policy mandate, the timing and messaging directly support your practice's visibility: the campaign emphasizes that treatment effectiveness and encourages individuals to seek care through FindTreatment.gov and FindSupport.gov, both of which list licensed therapists by credential and location. As an LCSW, LPC, MFT, or psychologist, your practice may see increased referrals during January and potentially throughout the year as awareness compounds. However, this campaign does not change reimbursement rates, prior authorization requirements, or insurance coverage policies—it simply increases demand. The real practice value lies in your preparedness: ensure your practice information is current and complete on SAMHSA's treatment locator databases, your website clearly articulates your SUD treatment capabilities (behavioral therapy for co-occurring mental health conditions, recovery support coordination), and your intake team can quickly assess whether patients have active SUDs that require medication management coordination with a prescriber. For therapists in private practice without prescribing partnerships, the campaign's emphasis on medication-assisted treatment (buprenorphine, methadone, naltrexone for OUD; acamprosate, disulfiram, naltrexone for AUD) means you should have clear referral pathways to medical providers or be prepared to work as part of a collaborative team. The campaign's framing—that SUDs are treatable, long-term health conditions with recurrence risk, requiring ongoing recovery support—aligns with evidence-based practice and reduces stigma, which indirectly benefits your credibility when counseling these patients. No immediate compliance burden exists, but practices should audit their online presence now to capture the visibility surge.
Background
SAMHSA launched SUD Treatment Month in January 2025 as part of a broader federal commitment to normalize substance use disorder treatment and reduce barriers to access. This initiative reflects ongoing recognition that the United States faces a persistent overdose crisis and high prevalence of untreated SUDs: the 2023 National Survey on Drug Use and Health found that 48.5 million Americans (17% of the population) experienced a SUD in the past year, yet treatment gaps remain substantial. The campaign also signals SAMHSA's intent to destigmatize SUDs by reframing them as treatable health conditions rather than moral failures, a shift that legitimizes therapist involvement in SUD treatment beyond traditional addiction counseling roles. The emphasis on integrated care—behavioral therapies combined with medications and peer support—reflects current clinical consensus and creates operational relevance for therapists who work in multidisciplinary settings or coordinate with psychiatrists and primary care providers. This public awareness push comes amid ongoing debates about insurance parity for mental health and substance use services, Medicaid expansion variations by state, and continued shortages of medication-assisted treatment providers in rural areas. For therapists, the campaign indirectly validates your role in the treatment continuum while making clear that medication management coordination is now standard expectation, not optional.
What you should do
Verify and update your practice profile on FindTreatment.gov and FindSupport.gov immediately—ensure your credentials (LCSW, LPC, MFT, psychologist), treatment specialties (SUD, co-occurring mental health), insurance accepted, and payment assistance options are accurately listed to capture January 2025 referral traffic.
Document your SUD screening and assessment protocols to align with DSM-5 criteria for severity determination (mild, moderate, severe) and ensure you can distinguish between active SUD that requires medical intervention versus substance use history; clarify on your intake forms whether you screen all patients for substance use and what your referral process is for MOUD/MAUD coordination.
If you do not currently have a warm referral relationship with a prescriber (psychiatrist, psychiatric NP, primary care physician) who manages MOUD or MAUD, establish one or develop a formal collaborative care agreement; document this in your practice manual so your team can respond when patients disclose opioid or alcohol use disorder.
Develop a one-page internal SUD treatment readiness checklist for clinicians covering: (1) whether you assess for SUD in every intake, (2) your role versus the medical prescriber's role, (3) how you document recovery support and behavioral therapy components separately from medication management, (4) your crisis protocol for patients at imminent overdose risk, and (5) how you track and report outcomes related to continued substance use.
Review your Medicaid and commercial insurance contracts to confirm coverage for behavioral health services provided to SUD patients specifically; note any prior authorization requirements, session limits, or requirement that a medical provider initiate treatment first—SUD Treatment Month referrals may include uninsured patients, so clarify your sliding scale or cash-pay capacity.
Notable excerpts
"SUDs are health conditions that typically develop over time in association with repeated substance use that changes the way the brain works. These changes can lead to compulsive cravings, reduced control over substance use, and continued use despite negative personal health and social consequences." (SAMHSA, January 2025)
"Research shows that many people with SUDs respond well to combinations of behavioral therapies, medications, and recovery supports." (SAMHSA, January 2025)
"In 2023, 48.5 million people 12 or older, or 17 percent of the U.S. population, had a SUD within the past year, according to SAMHSA's 2023 National Survey on Drug Use and Health (NSDUH)." (SAMHSA, January 2025)
"Not everyone with a SUD will experience addiction. That is especially true for alcohol use disorder, since most people with this condition have a mild severity." (SAMHSA, January 2025)
View full source text
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
One Student's Quick Thinking Shows Coordinated Action Through SAMHSA Program on Youth Mental Health Works
SAMHSA funding for school-based programs like Project AWARE generates referrals to therapists and expands youth access to mental health services. Therapists should understand these pipeline programs when engaging with schools.
On World AIDS Day, SAMHSA reaffirms commitment to Ending HIV Epidemic with support from partners
This signals federal funding and grant opportunities for therapists and agencies in high-burden HIV areas, particularly around integrated testing and treatment linkage. Therapists in targeted geographic areas should monitor MAI grant cycles.
Release of the 2024 National Survey on Drug Use and Health: Leveraging the Latest Substance Use and Mental Health Data to Make America Healthy Again
NSDUH data releases inform federal policy direction and funding priorities for behavioral health. Therapists should understand these epidemiological trends as they shape reimbursement, regulatory focus, and workforce demand.
New SAMHSA Guide Highlights HIV Prevention and Treatment for People with Substance Use and/or Mental Disorders
This SAMHSA clinical guidance can help therapists improve outcomes for high-risk populations with co-occurring conditions. It may also inform insurance companies' expectations for evidence-based treatment, potentially affecting prior authorization decisions.